Immunovant, Inc.
IMVT
$13.84
-$1.38-9.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.88M | 65.32M | 60.69M | 57.28M | 54.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 405.21M | 352.46M | 298.51M | 270.21M | 253.59M |
| Operating Income | -405.21M | -352.46M | -298.51M | -270.21M | -253.59M |
| Income Before Tax | -382.17M | -322.73M | -271.89M | -258.77M | -244.11M |
| Income Tax Expenses | 539.00K | 279.00K | 655.00K | 567.00K | -656.00K |
| Earnings from Continuing Operations | -382.71 | -323.01 | -272.55 | -259.34 | -243.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -382.71M | -323.01M | -272.55M | -259.34M | -243.45M |
| EBIT | -405.21M | -352.46M | -298.51M | -270.21M | -253.59M |
| EBITDA | -404.87M | -352.17M | -298.26M | -269.98M | -253.37M |
| EPS Basic | -2.62 | -2.22 | -1.92 | -1.89 | -1.83 |
| Normalized Basic EPS | -1.63 | -1.38 | -1.20 | -1.12 | -1.09 |
| EPS Diluted | -2.62 | -2.22 | -1.92 | -1.89 | -1.83 |
| Normalized Diluted EPS | -1.63 | -1.38 | -1.20 | -1.12 | -1.09 |
| Average Basic Shares Outstanding | 584.83M | 582.43M | 567.12M | 551.54M | 535.81M |
| Average Diluted Shares Outstanding | 584.83M | 582.43M | 567.12M | 551.54M | 535.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |